GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q3 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $195.3 million versus the consensus estimate of $195.66 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q4 2024 revenue of ~$200 million, versus the consensus of $206.2 million.

GoodRx Holdings, Inc. sees FY2024 revenue of ~$794 million, versus the consensus of $800.7 million.

For earnings history and earnings-related data on GoodRx Holdings, Inc. (GDRX) click here.